

Letermovir Prophylaxis for Cytomegalovirus in Hemato

New England Journal of Medicine

377, 2433-2444

DOI: [10.1056/nejmoa1706640](https://doi.org/10.1056/nejmoa1706640)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ambient Temperature and Screening for Nasopharyngeal Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 962-963.	13.9	18
2	Letermovir Prophylaxis for Cytomegalovirus. <i>New England Journal of Medicine</i> , 2018, 378, 963-965.	13.9	7
3	Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1914-1919.	2.0	9
4	Identification of Elite Neutralizers With Broad and Potent Neutralizing Activity Against Human Cytomegalovirus (HCMV) in a Population of HCMV-Seropositive Blood Donors. <i>Journal of Infectious Diseases</i> , 2018, 218, 876-885.	1.9	8
5	Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 897-904.	1.0	47
6	Reply to Giménez et al. <i>Clinical Infectious Diseases</i> , 2018, 67, 807-808.	2.9	1
7	Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy080.	0.4	13
8	Cytomegalovirus resistance in CD34 ⁺ selected hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12881.	0.7	11
9	Metal-chelating 3-hydroxypyrimidine-2,4-diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication. <i>Antiviral Research</i> , 2018, 152, 10-17.	1.9	19
10	Thymidine kinase and protein kinase in drug-resistant herpesviruses: Heads of a Lernaean Hydra. <i>Drug Resistance Updates</i> , 2018, 37, 1-16.	6.5	19
11	The human cytomegalovirus terminase complex as an antiviral target: a close-up view. <i>FEMS Microbiology Reviews</i> , 2018, 42, 137-145.	3.9	73
12	Letermovir: First Global Approval. <i>Drugs</i> , 2018, 78, 147-152.	4.9	47
13	The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	39
14	Immune Monitoring for CMV in Transplantation. <i>Current Infectious Disease Reports</i> , 2018, 20, 4.	1.3	47
15	Optimizing the management of cytomegalovirus infection in transplant patients. <i>Future Virology</i> , 2018, 13, 765-768.	0.9	0
16	Classification of death causes after transplantation (CLASS). <i>Medicine (United States)</i> , 2018, 97, e11564.	0.4	14
17	The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts. <i>Viruses</i> , 2018, 10, 614.	1.5	19
18	Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1197-1207.	1.5	9

#	ARTICLE	IF	CITATIONS
20	Pulmonary Infections in Immunocompromised Hosts. <i>Journal of Thoracic Imaging</i> , 2018, 33, 295-305.	0.8	8
21	Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial. <i>BMC Infectious Diseases</i> , 2018, 18, 573.	1.3	19
22	A Native Human Monoclonal Antibody Targeting HCMV gB (AD-2 Site I). <i>International Journal of Molecular Sciences</i> , 2018, 19, 3982.	1.8	17
23	Cytomegalovirus in Pediatric Hematopoietic Stem Cell Transplantation: A Case-Based Panel Discussion of Current Challenges. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, S72-S74.	0.6	11
24	Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34+ Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2734.	2.2	23
25	Large-Scale Screening of HCMV-Seropositive Blood Donors Indicates that HCMV Effectively Escapes from Antibodies by Cell-Associated Spread. <i>Viruses</i> , 2018, 10, 500.	1.5	14
26	A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection. <i>Expert Review of Vaccines</i> , 2018, 17, 889-911.	2.0	42
27	Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. <i>American Journal of Transplantation</i> , 2018, 18, 3060-3064.	2.6	103
28	Invasive fungal disease and cytomegalovirus infection: is there an association?. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 481-489.	1.3	47
29	Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. <i>F1000Research</i> , 2018, 7, 661.	0.8	7
30	Antiviral Drugs. <i>Side Effects of Drugs Annual</i> , 2018, , 345-361.	0.6	2
31	Pediatric transplantation case conference: Update on cytomegalovirus. <i>Pediatric Transplantation</i> , 2018, 22, e13276.	0.5	4
32	New therapies for human cytomegalovirus infections. <i>Antiviral Research</i> , 2018, 159, 153-174.	1.9	80
33	Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 2159-2175.	2.5	89
34	In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus. <i>Antiviral Research</i> , 2018, 158, 255-263.	1.9	21
35	Drug-resistant cytomegalovirus: clinical implications of specific mutations. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 388-394.	0.8	53
36	A Modified Intensive Strategy to Prevent Cytomegalovirus Disease in Seropositive Umbilical Cord Blood Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2094-2100.	2.0	23
37	Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2101-2109.	2.0	32

#	ARTICLE	IF	CITATIONS
38	Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2164-2165.	2.0	3
39	New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by <i>In Vitro</i> Exposure to Letemovir and Ganciclovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	50
40	New Developments in the Management of Cytomegalovirus Infection After Transplantation. <i>Drugs</i> , 2018, 78, 1085-1103.	4.9	84
41	Infections in Hematopoietic Stem Cell Transplant Recipients. , 2018, , 195-230.		1
42	Antiviral Treatment and Prophylaxis in Immunocompromised Hosts. , 2018, , 317-337.		0
44	Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2259-2264.	2.0	66
45	Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. <i>Antiviral Research</i> , 2018, 157, 128-133.	1.9	40
46	Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 256-276.	0.7	38
47	Letemovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (<sc>UL</sc>97 mutation). <i>Transplant Infectious Disease</i> , 2018, 20, e12965.	0.7	38
48	Letemovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 931-941.	1.3	17
49	Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 773-788.	1.3	14
50	Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor. <i>Bone Marrow Transplantation</i> , 2018, 53, 1351-1355.	1.3	13
51	Do opportunistic viruses hunt in packs?. <i>Reviews in Medical Virology</i> , 2018, 28, e1982.	3.9	1
52	Role of letemovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 286-291.	1.3	18
53	Drugs That Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs. <i>Side Effects of Drugs Annual</i> , 2018, , 489-505.	0.6	0
54	US28: HCMV's Swiss Army Knife. <i>Viruses</i> , 2018, 10, 445.	1.5	58
55	Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 581-597.	1.9	25
56	Antiviral Therapies for Herpesviruses: Current Agents and New Directions. <i>Clinical Therapeutics</i> , 2018, 40, 1282-1298.	1.1	90

#	ARTICLE	IF	CITATIONS
57	Prevention and treatment of cytomegalovirus in immunocompromised patients. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 263-266.	1.3	0
58	A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019, 68, 196-203.	2.9	41
59	Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. <i>Bone Marrow Transplantation</i> , 2019, 54, 90-98.	1.3	12
60	Letermovir associated hepatic transaminitis: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1235-1238.	0.5	5
61	Significant Publications on Infectious Diseases Pharmacotherapy in 2017. <i>Journal of Pharmacy Practice</i> , 2019, 32, 534-545.	0.5	8
62	Who is the best donor for haploidentical stem cell transplantation?. <i>Seminars in Hematology</i> , 2019, 56, 194-200.	1.8	15
63	An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2019, 12, 937-945.	1.0	6
64	An overview of letermovir: a cytomegalovirus prophylactic option. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1429-1438.	0.9	17
65	Herpesvirus Infections of the Central Nervous System. <i>Seminars in Neurology</i> , 2019, 39, 369-382.	0.5	17
66	Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. <i>Clinical Transplantation</i> , 2019, 33, e13666.	0.8	38
68	In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products. <i>Antiviral Research</i> , 2019, 169, 104549.	1.9	15
69	Battle between Host Immune Cellular Responses and HCMV Immune Evasion. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3626.	1.8	33
70	The clinical and economic burden of cytomegalovirus management post allogeneic hematopoietic stem cell transplantation in Japan – a retrospective database study. <i>Current Medical Research and Opinion</i> , 2019, 35, 2089-2096.	0.9	8
71	Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1481-1491.	1.1	88
72	Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. <i>American Journal of Transplantation</i> , 2019, 19, 2479-2494.	2.6	45
73	Risk Factors for Failure of Primary Ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz215.	0.4	21
74	Immunization of Rabbits with Recombinant Human Cytomegalovirus Trimeric versus Monomeric gH/gL Protein Elicits Markedly Higher Titers of Antibody and Neutralization Activity. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3158.	1.8	7
75	Patient-Derived Cytomegaloviruses with Different Ganciclovir Sensitivities from UL97 Mutation Retain Their Replication Efficiency and Some Kinase Activity In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	1

#	ARTICLE	IF	CITATIONS
76	Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. <i>Frontiers in Immunology</i> , 2019, 10, 2247.	2.2	463
77	Infectious Complications Following Kidney Transplantation—A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota. <i>Medicina (Lithuania)</i> , 2019, 55, 672.	0.8	7
78	Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. <i>Antiviral Research</i> , 2019, 172, 104639.	1.9	22
79	Prise en charge de l'infection à cytomégalo virus en transplantation. <i>Revue Francophone Des Laboratoires</i> , 2019, 2019, 36-43.	0.0	0
80	Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene. <i>Transplant Infectious Disease</i> , 2019, 21, e13168.	0.7	3
81	Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. <i>Transplant Infectious Disease</i> , 2019, 21, e13187.	0.7	62
82	Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13166.	0.7	40
83	Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. <i>Antiviral Research</i> , 2019, 172, 104616.	1.9	21
84	Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz375.	0.4	18
85	Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1017-1030.	1.0	29
86	CMV gastric ulcer in a patient with pauci immune crescentic glomerulonephritis on rituximab—a rare combination. <i>Postgraduate Medicine</i> , 2019, 131, 619-622.	0.9	2
87	Targeted in-vitro-stimulation reveals highly proliferative multi-virus-specific human central memory T cells as candidates for prophylactic T cell therapy. <i>PLoS ONE</i> , 2019, 14, e0223258.	1.1	5
88	CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019048.	0.5	9
89	Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. <i>Antiviral Research</i> , 2019, 163, 91-105.	1.9	66
90	Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2019, 29, e2034.	3.9	458
91	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. <i>Haematologica</i> , 2019, 104, 929-936.	1.7	23
92	Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit. , 2019, , 1-34.		0
94	<p>Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogeneic hematopoietic stem cell transplantation in Italy</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1127-1138.	1.1	14

#	ARTICLE	IF	CITATIONS
95	A post-transplant optimized transplant-specific risk score in myelodysplastic syndromes. <i>Haematologica</i> , 2019, 104, 859-861.	1.7	1
96	Advances in CMV infection prevention and treatment after allo-HSCT. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e53.	0.6	0
97	Antimicrobial Prophylaxis and Preemptive Approaches for the Prevention of Infections in the Stem Cell Transplant Recipient, with Analogies to the Hematologic Malignancy Patient. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 361-380.	1.9	11
98	Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Frontiers in Microbiology</i> , 2019, 10, 1186.	1.5	105
99	Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. <i>American Journal of Transplantation</i> , 2019, 19, 2457-2467.	2.6	28
100	Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13622.	0.8	71
101	Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and meta-analysis – Part II: Non-kidney transplant. <i>Clinical Transplantation</i> , 2019, 33, e13625.	0.8	14
102	Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). <i>Lancet Infectious Diseases</i> , The, 2019, 19, e260-e272.	4.6	285
103	Characterization of Viral Infections after Antithymocyte Globulin-Based Conditioning in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1837-1843.	2.0	6
104	Letermovir in paediatric HSCT recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2820-2821.	1.3	14
105	Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2666.	1.8	81
106	Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 96-99.	0.6	10
107	Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. <i>BMC Infectious Diseases</i> , 2019, 19, 388.	1.3	52
109	Cellular Cullin RING Ubiquitin Ligases: Druggable Host Dependency Factors of Cytomegaloviruses. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1636.	1.8	33
110	The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. <i>Annals of Hematology</i> , 2019, 98, 1755-1763.	0.8	35
111	Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia. <i>Transplant Infectious Disease</i> , 2019, 21, e13096.	0.7	46
112	Development of novel vaccines against human cytomegalovirus. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2673-2683.	1.4	16
113	High incidence of clinically significant cytomegalovirus infection in CMV D+/R+ lung transplant recipients receiving 3 months of antiviral prophylaxis. <i>Transplant Infectious Disease</i> , 2019, 21, e13094.	0.7	3

#	ARTICLE	IF	CITATIONS
114	Pharmacokinetic Drug-Drug Interactions Between Letemovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1331-1339.	1.0	47
115	Pharmacogenetic Analysis of OATP1B1 , UGT1A1 , and BCRP Variants in Relation to the Pharmacokinetics of Letemovir in Previously Conducted Clinical Studies. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1236-1243.	1.0	12
116	New vaccines and antiviral drugs for cytomegalovirus. <i>Journal of Clinical Virology</i> , 2019, 116, 58-61.	1.6	22
117	The N Terminus of Human Cytomegalovirus Glycoprotein O Is Important for Binding to the Cellular Receptor PDGFR α . <i>Journal of Virology</i> , 2019, 93, .	1.5	31
118	Antimicrobial Prophylaxis in High-Risk Oncology Patients. , 2019, , 1-15.		0
119	Interactions between anti-infective agents and immunosuppressants—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13510.	0.8	32
120	Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13512.	0.8	418
121	Viral infections after allogeneic hematopoietic stem cell transplant. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e43.	0.6	3
122	Control of viral infections by epigenetic-targeted therapy. <i>Clinical Epigenetics</i> , 2019, 11, 55.	1.8	67
123	Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2019, 208, 405-414.	2.6	3
124	Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13526.	0.8	75
125	Terminase Large Subunit Provides a New Drug Target for Herpesvirus Treatment. <i>Viruses</i> , 2019, 11, 219.	1.5	15
126	Synthetic Approaches to the New Drugs Approved During 2017. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7340-7382.	2.9	44
127	Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: A systematic review and meta-analysis. <i>Clinical Transplantation</i> , 2019, 33, e13560.	0.8	11
128	Cytomegalovirus Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 485-500.	1.9	21
129	Improved Survival after Cord Blood Transplantation: Single-Center Experience in Pediatric Patients Over a 2-Decade Period. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e117-e118.	2.0	0
130	Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S361-S362.	2.0	0
131	Turning cost effectiveness analysis on its head. <i>Reviews in Medical Virology</i> , 2019, 29, e2040.	3.9	0

#	ARTICLE	IF	CITATIONS
132	The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early-2 (IE2) protein transactivating activity.. <i>Antiviral Research</i> , 2019, 164, 52-60.	1.9	38
133	In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019001.	0.5	38
134	From academic research to founding a company: the story of AiCuris. <i>Pure and Applied Chemistry</i> , 2019, 91, 717-728.	0.9	0
135	Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of In Vitro Screenings. <i>MSphere</i> , 2019, 4, .	1.3	7
136	â€œMiniâ€ bank of only 8 donors supplies CMV-directed T cells to diverse recipients. <i>Blood Advances</i> , 2019, 3, 2571-2580.	2.5	44
137	Mechanisms of AIDS-related cytomegalovirus retinitis. <i>Future Virology</i> , 2019, 14, 545-560.	0.9	4
138	CMV Prevention and Treatment in Transplantation: Whatâ€™s New in 2019. <i>Current Infectious Disease Reports</i> , 2019, 21, 45.	1.3	22
139	Opportunistic Infections in Transplant Patients. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 1143-1157.	1.9	41
141	Cytomegalovirus infection in immunocompetent critically ill patients. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2019, 26, 5-11.	0.0	0
142	Adoptive cell therapies for posttransplant infections. <i>Current Opinion in Oncology</i> , 2019, 31, 574-590.	1.1	12
143	Human herpesvirus 6 in transplant recipients: an update on diagnostic and treatment strategies. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 584-590.	1.3	29
144	Antiviral drugs. <i>Side Effects of Drugs Annual</i> , 2019, , 301-319.	0.6	4
145	New treatments for cytomegalovirus in transplant patients. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 587-592.	1.0	2
146	Update on prevention of cytomegalovirus in hematopoietic cell transplantation. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 63-68.	1.3	2
147	Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 565-574.	1.3	10
148	Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies. <i>Frontiers in Immunology</i> , 2019, 10, 2794.	2.2	12
149	Updates on antiviral drugs for cytomegalovirus prevention and treatment. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 469-475.	0.8	30
150	Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 784-798.	1.0	9

#	ARTICLE	IF	CITATIONS
151	Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 771-784.	2.0	12
152	Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis. <i>Expert Review of Hematology</i> , 2019, 12, 47-60.	1.0	19
153	Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. <i>Blood</i> , 2019, 133, 867-877.	0.6	42
154	Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis. <i>Bone Marrow Transplantation</i> , 2019, 54, 911-912.	1.3	31
155	Infections in Hematology Patients. , 2019, , 503-518.		2
156	Medical Course and Complications After Hematopoietic Cell Transplantation. , 2019, , 417-438.		0
157	Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections. <i>Antiviral Research</i> , 2019, 161, 116-124.	1.9	29
158	Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 791-799.	2.0	7
159	Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients. <i>Future Microbiology</i> , 2019, 14, 175-184.	1.0	3
160	Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation. <i>Science</i> , 2019, 363, 288-293.	6.0	49
161	Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	73
162	FRET-based assay using a three-way junction DNA substrate to identify inhibitors of human cytomegalovirus pUL89 endonuclease activity. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 29-37.	1.9	3
163	Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 577-586.	2.0	32
164	Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	12
165	Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1255-1264.	2.9	137
166	Advances in ex vivo T cell depletion - where do we stand?. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e29.	0.6	3
167	Clinical and Economic Impact of Cytomegalovirus Infection among Children Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1253-1259.	2.0	16
168	Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 105-119.	1.0	34

#	ARTICLE	IF	CITATIONS
169	Restriction of Human Cytomegalovirus Infection by Galectin-9. <i>Journal of Virology</i> , 2019, 93, .	1.5	18
170	The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2019, 219, 898-907.	1.9	52
171	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 369-381.	2.0	151
172	Infectious disease risks in pediatric renal transplantation. <i>Pediatric Nephrology</i> , 2019, 34, 1155-1166.	0.9	16
173	To Bridge, Blossom, or Boost: That Is the Question. <i>Clinical Infectious Diseases</i> , 2020, 70, 1438-1441.	2.9	0
174	Cytomegalovirus Viremia and Death After Hematopoietic Cell Transplantation: More Complex Than "To Have and Have Not". <i>Clinical Infectious Diseases</i> , 2020, 70, 1534-1535.	2.9	1
176	A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 70, 1525-1533.	2.9	100
177	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 12-24.	1.3	94
178	Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. <i>Current Medical Research and Opinion</i> , 2020, 36, 33-41.	0.9	4
179	Impact of Cytomegalovirus Reactivation and Natural Killer Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 171-177.	2.0	7
180	Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 1152-1158.	1.0	7
181	New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation. <i>Internal Medicine Journal</i> , 2020, 50, 277-284.	0.5	12
182	Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 486-489.	0.6	23
183	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	1.3	196
184	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2020, 209, 15-21.	2.6	8
186	Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 568-580.	2.0	8
187	CMV infection management in transplant patients in Italy. <i>Journal of Clinical Virology</i> , 2020, 123, 104211.	1.6	8
188	Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 780-786.	1.3	31

#	ARTICLE	IF	CITATIONS
189	Wealth transfer through private placements: Evidence from China. <i>Financial Review</i> , 2020, 55, 199-219.	1.3	2
190	Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2020, 26, 189-198.	2.8	10
191	A highly potent trimeric derivative of artesunate shows promising treatment profiles in experimental models for congenital HCMV infection in vitro and ex vivo. <i>Antiviral Research</i> , 2020, 175, 104700.	1.9	14
192	Incidence and Risk Factors for Acute and Chronic Kidney Injury after Adult Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 758-763.	2.0	14
193	Clinically significant drug interaction: letermovir and voriconazole. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 775-777.	1.3	22
194	Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2020, 221, 1117-1126.	1.9	48
195	De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance. <i>Journal of Infectious Diseases</i> , 2020, 221, 1480-1487.	1.9	10
196	Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients. <i>Transplantation</i> , 2020, 104, 410-414.	0.5	28
197	Impact of CMV Reactivation, Treatment Approaches, and Immune Reconstitution in a Nonmyeloablative Tolerance Induction Protocol in Cynomolgus Macaques. <i>Transplantation</i> , 2020, 104, 270-279.	0.5	3
198	Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients. <i>Transplantation</i> , 2020, 104, 404-409.	0.5	41
199	Letermovir Resistance in Hematopoietic Stem Cell Transplant Recipients: The Risks Associated with Cytomegalovirus Prophylaxis. <i>Journal of Infectious Diseases</i> , 2020, 221, 1036-1038.	1.9	3
200	Cytomegalovirus: The "Troll of Transplantation" Is Now the "Troll of Tolerance". <i>Transplantation</i> , 2020, 104, 238-239.	0.5	2
201	Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1703-1711.	2.6	42
202	Antiviral Agents as Therapeutic Strategies Against Cytomegalovirus Infections. <i>Viruses</i> , 2020, 12, 21.	1.5	36
203	Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status. <i>Current Research in Translational Medicine</i> , 2020, 68, 131-137.	1.2	3
204	Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	13
205	Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation " A Single Centre Study. <i>Anticancer Research</i> , 2020, 40, 5909-5917.	0.5	12
206	Letermovir salvage therapy in the management of a case of cytomegalovirus ventriculitis complicated by drug resistance. <i>Clinical Infection in Practice</i> , 2020, 7-8, 100039.	0.2	2

#	ARTICLE	IF	CITATIONS
207	Reducing infectious complications after allogeneic stem cell transplant. Expert Review of Hematology, 2020, 13, 1235-1251.	1.0	4
208	Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?. Leukemia, 2020, 34, 2552-2560.	3.3	9
209	Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2020, 61, 3024-3026.	0.6	2
210	Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, 1963-1970.	2.0	26
211	Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV. PLoS Pathogens, 2020, 16, e1008560.	2.1	16
212	Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant. Therapeutic Advances in Hematology, 2020, 11, 204062072093715.	1.1	20
214	Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2021, 73, 156-160.	2.9	26
215	A hidden menace? Cytomegalovirus infection is associated with reduced cortical gray matter volume in major depressive disorder. Molecular Psychiatry, 2021, 26, 4234-4244.	4.1	19
216	Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients. Annals of Internal Medicine, 2020, 172, 306.	2.0	45
217	Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. Annals of Hematology, 2021, 100, 2087-2093.	0.8	29
218	British HIV Association guidelines on the management of opportunistic infection in people living with HIV: the clinical management of gastrointestinal opportunistic infections 2020. HIV Medicine, 2020, 21, 1-19.	1.0	3
219	A Novel, Broad-Acting Peptide Inhibitor of Double-Stranded DNA Virus Gene Expression and Replication. Frontiers in Microbiology, 2020, 11, 601555.	1.5	8
220	The Artemisinin-Derived Autofluorescent Compound BG95 Exerts Strong Anticytomegaloviral Activity Based on a Mitochondrial Targeting Mechanism. International Journal of Molecular Sciences, 2020, 21, 5578.	1.8	6
221	Evolution of the role of haploidentical stem cell transplantation: past, present, and future. Expert Review of Hematology, 2020, 13, 835-850.	1.0	11
222	Unintentional human leukocyte antigen mismatched haematopoietic cell transplant: clinical course and root cause analysis. British Journal of Haematology, 2020, 191, e35-e37.	1.2	0
223	Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms, 2020, 8, 1078.	1.6	32
224	The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2. International Journal of Pharmaceutics, 2020, 588, 119689.	2.6	46
225	Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 1694.	2.2	14

#	ARTICLE	IF	CITATIONS
226	Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2659-2670.	0.8	13
227	Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e275-e279.	2.0	11
228	Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2147-2154.	2.0	4
229	Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. <i>Journal of Infectious Diseases</i> , 2022, 226, 576-584.	1.9	42
230	Toward a cure in relapsed ALL: we must do better. <i>Leukemia and Lymphoma</i> , 2020, 61, 2544-2545.	0.6	0
231	Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation. <i>Clinical Microbiology Reviews</i> , 2020, 34, .	5.7	45
232	Advances in drug therapies for cytomegalovirus in transplantation: a focus on maribavir and letermovir. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 393-401.	0.5	5
233	Quantification of letermovir in human serum using high-performance liquid chromatography with diode array detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1159, 122399.	1.2	4
234	Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e715-e723.	2.2	8
235	Difficult Balance Between Multidrug-Resistant Cytomegalovirus Infection and Graft-Versus-Host Disease in an Allogeneic Hematopoietic Stem Cell Transplant Recipient. <i>Infectious Diseases in Clinical Practice</i> , 2020, 28, 257-260.	0.1	1
236	How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. <i>Blood</i> , 2020, 136, 2741-2753.	0.6	6
237	Advances in CMV Management: A Single Center Real-Life Experience. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 534268.	1.8	16
238	Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient. <i>Transplantation</i> , 2020, 104, e248-e249.	0.5	8
239	DNA Encapsidation and Capsid Assembly Are Underexploited Antiviral Targets for the Treatment of Herpesviruses. <i>Frontiers in Microbiology</i> , 2020, 11, 1862.	1.5	8
240	Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2453-2454.	0.8	1
241	Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality. <i>Clinical Infectious Diseases</i> , 2021, 73, e620-e628.	2.9	16
242	T-cell receptor repertoire of cytomegalovirus-specific cytotoxic T-cells after allogeneic stem cell transplantation. <i>Scientific Reports</i> , 2020, 10, 22218.	1.6	7
243	Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. <i>Transplant Infectious Disease</i> , 2021, 23, e13521.	0.7	18

#	ARTICLE	IF	CITATIONS
244	Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 810-816.	0.4	8
245	Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong. <i>Journal of Medical Economics</i> , 2020, 23, 1485-1492.	1.0	11
246	Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	23
247	Infection prophylaxis and management of viral infection. <i>Annals of Translational Medicine</i> , 2020, 8, 415-415.	0.7	14
248	Oxygen. <i>Bone Marrow Transplantation</i> , 2020, 55, 2057-2059.	1.3	0
249	How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2020, 135, 1619-1629.	0.6	96
250	Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. <i>Blood</i> , 2020, 135, 1739-1749.	0.6	176
251	The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1068-1074.	1.0	21
252	In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. <i>Journal of Infection and Public Health</i> , 2020, 13, 1210-1223.	1.9	203
253	Incidence of viral and fungal complications after utilization of alternative donor sources in hematopoietic cell transplantation. <i>Pharmacotherapy</i> , 2020, 40, 773-787.	1.2	4
254	Advances in the Development of Therapeutics for Cytomegalovirus Infections. <i>Journal of Infectious Diseases</i> , 2020, 221, S32-S44.	1.9	43
255	Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence. <i>Journal of Infectious Diseases</i> , 2020, 221, S23-S31.	1.9	80
256	The Development of Therapeutics for the Treatment and Prevention of CMV Disease in the Transplant Population: A Regulatory Perspective. <i>Journal of Infectious Diseases</i> , 2020, 221, S109-S112.	1.9	8
257	Scientific and Regulatory Considerations for Efficacy Studies of Cytomegalovirus Vaccines. <i>Journal of Infectious Diseases</i> , 2020, 221, S103-S108.	1.9	6
258	Pulmonary infections in the hematopoietic cell transplant patient. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 1.	1.3	6
259	Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 444-455.	0.8	3
260	Make Sure You Have a Safety Net: Updates in the Prevention and Management of Infectious Complications in Stem Cell Transplant Recipients. <i>Journal of Clinical Medicine</i> , 2020, 9, 865.	1.0	6
261	Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e13866.	0.8	48

#	ARTICLE	IF	CITATIONS
262	Cytomegalovirus in Adult Allogeneic Blood and Marrow Transplant Patients Before or Around the Period of Neutrophil Recovery: A Single-Center, Retrospective, Descriptive Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa081.	0.4	3
263	Improving the Odds. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e173-e174.	2.0	1
264	Translation of the long-term fundamental studies on viral DNA packaging motors into nanotechnology and nanomedicine. <i>Science China Life Sciences</i> , 2020, 63, 1103-1129.	2.3	4
265	Prevention and management of infections. , 2020, , 1113-1127.		0
266	Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13255.	0.7	9
267	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. <i>Bone Marrow Transplantation</i> , 2020, 55, 1773-1783.	1.3	35
268	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1084-1090.	2.0	19
269	Cytomegalovirus infection during pregnancy: state of the science. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 330-349.	0.7	136
270	Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1264-1271.	1.3	21
271	Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia. <i>Transplant Infectious Disease</i> , 2020, 22, e13233.	0.7	1
272	Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 2365-2374.	2.9	36
273	Potential Therapeutic Approaches Against Brain Diseases Associated with Cytomegalovirus Infections. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1376.	1.8	1
274	Modeling Human Cytomegalovirus in Humanized Mice for Vaccine Testing. <i>Vaccines</i> , 2020, 8, 89.	2.1	11
275	The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination. <i>Antiviral Research</i> , 2020, 176, 104732.	1.9	24
276	Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1687-1689.	1.3	9
277	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , 2020, 55, 1093-1102.	1.3	78
278	Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. <i>Antiviral Research</i> , 2020, 176, 104711.	1.9	66
279	The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease. <i>Antiviral Research</i> , 2020, 176, 104710.	1.9	10

#	ARTICLE	IF	CITATIONS
280	Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 90-102.	1.2	27
281	Cytomegalovirus Retinitis in HIV and Non-HIV Individuals. <i>Microorganisms</i> , 2020, 8, 55.	1.6	56
282	Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 911-919.	2.0	8
283	Infections after Allogeneic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1179-1188.	2.0	49
284	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 972-977.	2.0	11
285	Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 978-984.	2.0	49
286	Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection. <i>PLoS ONE</i> , 2020, 15, e0232140.	1.1	13
287	Virus-specific T-cell therapies for patients with primary immune deficiency. <i>Blood</i> , 2020, 135, 620-628.	0.6	45
288	Human Cytomegalovirus Prophylaxis and Treatment in Lung Transplantation in the Current Era. <i>Current Pulmonology Reports</i> , 2020, 9, 10-27.	0.5	0
289	Ageing Fits the Disease Criteria of the International Classification of Diseases. <i>Mechanisms of Ageing and Development</i> , 2020, 189, 111230.	2.2	26
290	Immunization with Human Cytomegalovirus Core Fusion Machinery and Accessory Envelope Proteins Elicit Strong Synergistic Neutralizing Activities. <i>Vaccines</i> , 2020, 8, 179.	2.1	6
291	Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study. <i>International Journal of Medical Sciences</i> , 2020, 17, 859-864.	1.1	7
292	Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation. <i>Journal of Medical Virology</i> , 2020, 92, 3665-3673.	2.5	8
293	Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1535-1548.	2.0	2
294	Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1482-1491.	2.0	27
295	Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 1051-1061.	2.5	17
296	Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin. <i>Blood Advances</i> , 2020, 4, 191-202.	2.5	36
297	Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 363-374.	1.7	26

#	ARTICLE	IF	CITATIONS
298	Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. <i>Leukemia</i> , 2021, 35, 143-155.	3.3	52
299	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. <i>American Journal of Transplantation</i> , 2021, 21, 258-271.	2.6	11
300	FLAG-sequential regimen followed by bone marrow transplantation for myelodysplastic syndrome or acute leukemia in patients with Fanconi anemia: a Franco-Brazilian study. <i>Bone Marrow Transplantation</i> , 2021, 56, 285-288.	1.3	5
301	Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 853-862.	1.3	42
302	Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. <i>Annals of Hematology</i> , 2021, 100, 169-180.	0.8	14
303	Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 198-206.	0.8	10
304	Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia after an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of the Japan Society for Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 82.e1-82.e8.	0.6	5
305	Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 85.e1-85.e6.	0.6	25
306	Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease. <i>Transplant Infectious Disease</i> , 2021, 23, e13487.	0.7	14
307	Infectious complications in allogeneic hematopoietic cell transplant recipients: Review of transplant-related risk factors and current state of prophylaxis. <i>Clinical Transplantation</i> , 2021, 35, e14172.	0.8	9
308	Cell therapy for cytomegalovirus infection. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 649-659.	1.4	9
309	Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13502.	0.7	3
310	Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1171-1179.	1.3	30
311	Approach to the patient with infectious colitis: clinical features, work-up and treatment. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 66-75.	1.0	3
312	Incorporation of posttransplant cyclophosphamide as part of standard immunoprophylaxis for all allogeneic transplants: a retrospective, single institution study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1099-1105.	1.3	10
313	Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. <i>Bone Marrow Transplantation</i> , 2021, 56, 1281-1290.	1.3	3
314	Cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation under cytomegalovirus antigenemia-guided active screening. <i>Bone Marrow Transplantation</i> , 2021, 56, 1266-1271.	1.3	6
315	Scoring system for clinically significant CMV infection in seropositive recipients following allogeneic hematopoietic cell transplant: an SFGM-TC study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1305-1315.	1.3	13

#	ARTICLE	IF	CITATIONS
316	Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 187.e1-187.e4.	0.6	4
317	Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective. <i>Journal of Medical Virology</i> , 2021, 93, 3786-3794.	2.5	14
318	A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a preemptive strategy in intermediate-risk patients: Combining the best of two options?. <i>Transplant Infectious Disease</i> , 2021, 23, e13467.	0.7	7
319	Letermovir for the compassionate therapeutic use of cytomegalovirus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 435-439.	1.3	9
320	Letermovir for the Management of Cytomegalovirus-associated Uveitis. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 169-174.	1.0	6
321	Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs). <i>International Journal of Molecular Sciences</i> , 2021, 22, 575.	1.8	22
322	Improving Outcomes for Children Requiring Extracorporeal Membrane Oxygenation Therapy Following Hematopoietic Stem Cell Transplantation. <i>Critical Care Medicine</i> , 2021, 49, e381-e393.	0.4	12
323	Stem Cell Transplantation: Infection Risk by Transplant Type and Emerging Trends in Infection Management. , 2021, , 43-82.		0
324	Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients: Prevention, Diagnosis, and Treatment. , 2021, , 573-616.		0
325	New Approaches to Allogeneic Haematopoietic Cell Transplantation. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 28.	0.1	0
326	Anti-infection Strategies. , 2021, , 164-179.		1
327	Coronavirus disease 2019 as a syndemic. <i>Reviews in Medical Virology</i> , 2021, 31, e2212.	3.9	0
328	Antimicrobial Prophylaxis in the Age of Emerging Transplant Infections. , 2021, , 155-170.		0
329	Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance. <i>Transplant Infectious Disease</i> , 2021, 23, e13548.	0.7	7
330	Other Diseases of the Esophagus. , 2021, , 238-244.e2.		0
331	Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines. <i>Methods in Molecular Biology</i> , 2021, 2244, 403-463.	0.4	5
332	CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	35
333	Treatment of Secondary Immunodeficiencies. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
334	Special Clinical Scenarios: Infectious Complications and Prophylaxis. Hematologic Malignancies, 2021, , 285-292.	0.2	0
336	Early high dose corticosteroid therapy in hematopoietic stem cell transplantation patients with acute respiratory distress syndrome: a propensity score matched study. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110093.	1.0	3
337	Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation. Therapeutic Advances in Hematology, 2021, 12, 204062072199812.	1.1	4
339	Insight for Immunotherapy of HCMV Infection. International Journal of Biological Sciences, 2021, 17, 2899-2911.	2.6	7
340	Management of Cellular Immunodeficiencies. Rare Diseases of the Immune System, 2021, , 441-453.	0.1	0
341	Antiviral Classification. , 2021, , 121-130.		10
342	Management of Herpesvirus Infections in Hematopoietic Cell Transplant Recipients. Transplantation, 2021, 2, 8-21.	0.3	6
343	Early T cell reconstitution and cytokine profile may help to guide a personalized management of human cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Journal of Clinical Virology, 2021, 135, 104734.	1.6	5
344	Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation. Annals of Intensive Care, 2021, 11, 33.	2.2	24
345	Letemovir prophylaxis in solid organ transplantâ€”Assessing CMV breakthrough and tacrolimus drug interaction. Transplant Infectious Disease, 2021, 23, e13570.	0.7	21
346	Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution. American Journal of Hematology, 2021, 96, 436-445.	2.0	18
347	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. Journal of Clinical Oncology, 2021, 39, 487-498.	0.8	27
348	Positive HCMV DNAemia in stem cell recipients undergoing letemovir prophylaxis is expression of abortive infection. American Journal of Transplantation, 2021, 21, 1622-1628.	2.6	35
349	Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation (Review). Oncology Letters, 2021, 21, 318.	0.8	5
350	Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMVâ€”IG prophylaxis: A monocentric retrospective analysis. Journal of Medical Virology, 2021, 93, 6292-6300.	2.5	3
351	Structures and Divergent Mechanisms in Capsid Maturation and Stabilization Following Genome Packaging of Human Cytomegalovirus and Herpesviruses. Life, 2021, 11, 150.	1.1	11
352	Drug interaction between letemovir and voriconazole after allogeneic hematopoietic cell transplantation. International Journal of Hematology, 2021, 113, 872-876.	0.7	15
353	Letemovir and HCT: too much of a good thing?. Blood, 2021, 138, 1-2.	0.6	6

#	ARTICLE	IF	CITATIONS
354	Expect the unexpected. <i>Blood</i> , 2021, 137, 3163-3164.	0.6	0
356	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021, 33, 100787.	3.2	14
357	Cytomegalovirus antiviral stewardship in the COVID-19 Era: Increasing complexity of prophylaxis and treatment and potential mitigation strategies. <i>Transplant Infectious Disease</i> , 2021, 23, e13586.	0.7	9
358	Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. <i>Blood</i> , 2021, 138, 34-43.	0.6	71
359	Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 478.e1-478.e5.	0.6	12
360	Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 255-267.	1.3	12
361	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 3291-3305.	0.6	85
362	Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid Malignancies: A Single Arm Phase II Study. <i>Frontiers in Medicine</i> , 2021, 8, 630160.	1.2	6
363	Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1185-1190.	1.1	16
364	Infectious Gastroenteritis in Transplant Patients. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 415-430.	1.0	1
365	Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 666091.	1.3	11
366	Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial. <i>PharmacoEconomics - Open</i> , 2021, 5, 469-473.	0.9	8
367	Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation. <i>Transplant Infectious Disease</i> , 2021, 23, e13617.	0.7	5
368	Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study. <i>Vaccines</i> , 2021, 9, 372.	2.1	22
369	Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficiency virus infection. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 168-176.	1.5	14
370	Cytomegalovirus Viral Load Kinetics Predict Cytomegalovirus End-Organ Disease and Mortality After Hematopoietic Cell Transplant. <i>Journal of Infectious Diseases</i> , 2021, 224, 620-631.	1.9	13
371	The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen. <i>Annals of Hematology</i> , 2021, 100, 1879-1889.	0.8	2
372	Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. <i>Clinical Infectious Diseases</i> , 2021, 73, 1346-1354.	2.9	43

#	ARTICLE	IF	CITATIONS
373	Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide. <i>Frontiers in Oncology</i> , 2021, 11, 666774.	1.3	5
374	Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia. <i>Transplantation</i> , 2021, 2, 129-139.	0.3	5
375	Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 342.e1-342.e10.	0.6	3
376	Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice. <i>Vaccines</i> , 2021, 9, 551.	2.1	43
377	Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	5
378	Cytomegalovirus events in high-risk allogeneic hematopoietic cell transplantation patients who received letermovir prophylaxis. <i>Transplant Infectious Disease</i> , 2021, 23, e13619.	0.7	8
379	T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection. <i>Bone Marrow Transplantation</i> , 2021, 56, 2582-2590.	1.3	2
380	HCMV Antivirals and Strategies to Target the Latent Reservoir. <i>Viruses</i> , 2021, 13, 817.	1.5	25
381	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 428.e1-428.e9.	0.6	11
382	Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. <i>Transplant Infectious Disease</i> , 2021, 23, e13627.	0.7	5
383	Guidelines for Infection Prophylaxis, Monitoring and Therapy in Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 359-362.	0.6	12
384	Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 771-776.	1.3	13
385	Assessing the differential impact of chronic CMV and treated HIV infection on CD8+ T-cell differentiation in a matched cohort study: is CMV the key?. <i>AIDS Research and Therapy</i> , 2021, 18, 37.	0.7	1
386	Cytomegalovirus as an Uninvited Guest in the Response to Vaccines in People Living with HIV. <i>Viruses</i> , 2021, 13, 1266.	1.5	14
387	Use of letermovir+valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14401.	0.8	6
388	A eulogy for Dr Francisco Miguel Marty Forero. <i>Transplant Infectious Disease</i> , 2021, 23, e13645.	0.7	0
389	Selection of Human Cytomegalovirus Mutants with Resistance against PDGFR β -Derived Entry Inhibitors. <i>Viruses</i> , 2021, 13, 1094.	1.5	3
390	Prophylactic pretransplant ganciclovir to reduce cytomegalovirus infection after hematopoietic stem cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	2

#	ARTICLE	IF	CITATIONS
391	Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study. <i>American Journal of Transplantation</i> , 2021, 21, 3449-3455.	2.6	12
392	Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 341-348.	1.5	19
393	High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13633.	0.7	3
394	Factors associated with neutropenia post heart transplantation. <i>Transplant Infectious Disease</i> , 2021, 23, e13634.	0.7	5
395	Association between Antiviral Prophylaxis and Cytomegalovirus and Epstein-Barr Virus DNAemia in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplant. <i>Vaccines</i> , 2021, 9, 610.	2.1	2
396	Pathogenesis of human cytomegalovirus in the immunocompromised host. <i>Nature Reviews Microbiology</i> , 2021, 19, 759-773.	13.6	243
397	Update on cytomegalovirus in transplant recipients: new agents, prophylaxis, and cell-mediated immunity. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 307-313.	1.3	14
398	Bone marrow transplantation for acquired aplastic anemia: What's new. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101284.	0.7	5
399	Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust. <i>HemaSphere</i> , 2021, 5, e580.	1.2	6
400	Are the Healthy Vulnerable? Cytomegalovirus Seropositivity in Healthy Adults Is Associated With Accelerated Epigenetic Age and Immune Dysregulation. <i>Journal of Infectious Diseases</i> , 2022, 225, 443-452.	1.9	13
401	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. <i>American Journal of Hematology</i> , 2021, 96, 1186-1194.	2.0	17
402	Fluorodeoxyglucose F 18 for the Assessment of Acute Intestinal Graft-versus-Host Disease and Prediction of Response to Immunosuppressive Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 603-610.	0.6	8
403	Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 940-948.	0.6	20
404	Incidence of CMV Infection and Disease and Adverse Events Associated with Antiviral Therapy in a Retrospective Cohort of Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children's Hospital. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 910-918.	0.6	5
405	Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13687.	0.7	34
406	Prevention and management of infections after exposure to ionizing radiation. <i>Journal of Radiological Protection</i> , 2021, 41, .	0.6	1
407	Development and Full Validation of a Bioanalytical Method for Quantifying Letermovir in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry. <i>Chemical and Pharmaceutical Bulletin</i> , 2021, 69, 646-651.	0.6	2
408	CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies. <i>Current Treatment Options in Infectious Diseases</i> , 2021, 13, 123-140.	0.8	23

#	ARTICLE	IF	CITATIONS
409	New Insights into Human Cytomegalovirus pUL52 Structure. <i>Viruses</i> , 2021, 13, 1638.	1.5	3
410	Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients. <i>Blood Advances</i> , 2021, 5, 3113-3119.	2.5	24
411	Epidemiological changes in cytomegalovirus end-organ diseases in a developed country: A nationwide, general-population-based study. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 812-819.	1.5	1
412	Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 686.e1-686.e9.	0.6	3
413	Prediction of Cytomegalovirus Reactivation by Recipient Cytomegalovirus-IgG Titer before Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 683.e1-683.e7.	0.6	6
414	Next-generation sequencing for cytomegalovirus antiviral resistance genotyping in a clinical virology laboratory. <i>Antiviral Research</i> , 2021, 192, 105123.	1.9	14
415	Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients. <i>Microorganisms</i> , 2021, 9, 1666.	1.6	1
416	Management of refractory and resistant CMV: A step forward but more work needed. <i>Transplant Infectious Disease</i> , 2021, 23, e13704.	0.7	0
417	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , 2021, 62, 3373-3383.	0.6	12
418	Association between the kinetics of cytomegalovirus reactivation in terms of the area under the curve of cytomegalovirus antigenemia and non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2021, 23, e13715.	0.7	2
419	Elucidation of Metabolic and Disposition Pathways for Maribavir in Non-human Primates Through Mass Balance and Semi-Physiologically Based Modeling Approaches. <i>Drug Metabolism and Disposition</i> , 2021, 49, DMD-AR-2021-000493.	1.7	5
420	Farewell, Francisco. <i>Transplant Infectious Disease</i> , 2021, 23, e13703.	0.7	0
421	Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 3042-3048.	1.3	4
422	Association between cytomegalovirus infection, reduced gray matter volume, and resting-state functional hypoconnectivity in major depressive disorder: a replication and extension. <i>Translational Psychiatry</i> , 2021, 11, 464.	2.4	11
423	American Society for Transplantation and Cellular Therapy Series: #3 Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 707-719.	0.6	45
424	Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes. <i>Annals of Hematology</i> , 2021, 100, 2773-2785.	0.8	6
425	Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience. <i>Frontiers in Oncology</i> , 2021, 11, 740079.	1.3	19
427	Lower incidence of Cytomegalovirus reactivation following post-transplant cyclophosphamide HLA mismatched unrelated donor transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1017.e1-1017.e1.	0.6	5

#	ARTICLE	IF	CITATIONS
428	Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 994.	1.3	11
429	Current research status of cytomegalovirus infection after hematopoietic stem cell transplantation: a bibliometric analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 9614-9626.	0.5	4
430	American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 957-967.	0.6	26
431	Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2083-2097.	1.2	5
432	Peptide Derivatives of Platelet-Derived Growth Factor Receptor Alpha Inhibit Cell-Associated Spread of Human Cytomegalovirus. <i>Viruses</i> , 2021, 13, 1780.	1.5	3
433	A Prospective Viral Monitoring Study After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Nonmalignant Diseases. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 872.e1-872.e8.	0.6	8
434	Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation. <i>Life</i> , 2021, 11, 102.	1.1	8
435	Cytomegalovirus in Solid Organ Transplant Recipients: Prevention, Diagnosis, and Treatment. , 2021, , 547-571.		0
436	Replicable association between human cytomegalovirus infection and reduced white matter fractional anisotropy in major depressive disorder. <i>Neuropsychopharmacology</i> , 2021, 46, 928-938.	2.8	16
437	Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWPâ€“EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1563-1572.	1.3	1
438	Pulmonary Syndromes in Transplantation. , 2021, , 1615-1637.		0
439	The Toll of Prophylaxis: Cytomegalovirus Infection in the Haploidentical Donor and Post-transplant Cyclophosphamide Era. , 2021, 18, .		0
440	Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Medical Microbiology</i> , 2018, 67, 814-819.	0.7	2
441	Randomised controlled trial of conditioning regimen for cord blood transplantation for adult myeloid malignancies comparing high-dose cytarabine/cyclophosphamide/total body irradiation with versus without G-CSF priming: G-CONCORD study protocol. <i>BMJ Open</i> , 2020, 10, e040467.	0.8	4
442	Early antibiotic use is associated with CMV risk and outcomes following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 6364-6367.	2.5	5
444	Novel Strategies to Combat CMV-Related Cardiovascular Disease. <i>Pathogens and Immunity</i> , 2020, 5, 240.	1.4	18
445	Prophylaxis vs preemptive therapy in prevention of CMV infection: new insight on prophylactic strategy after allogeneic hematopoietic cell transplantation. <i>Acta Haematologica Polonica</i> , 2020, 51, 17-23.	0.1	10
446	Congenital Cytomegalovirus Infection. <i>Ochsner Journal</i> , 2019, 19, 123-130.	0.5	32

#	ARTICLE	IF	CITATIONS
447	History of hematopoietic cell transplantation: challenges and progress. <i>Haematologica</i> , 2020, 105, 2716-2729.	1.7	54
448	Cytomegalovirus infection after liver transplantation. <i>World Journal of Transplantation</i> , 2020, 10, 183-190.	0.6	21
449	Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. <i>Drugs in R and D</i> , 2021, 21, 419-429.	1.1	3
450	Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting. <i>Blood Advances</i> , 2021, 5, 4500-4503.	2.5	6
451	Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 485-495.	2.3	1
452	Cytomegalovirus Infections in Children with Primary and Secondary Immune Deficiencies. <i>Viruses</i> , 2021, 13, 2001.	1.5	13
453	Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2021, 115, 96.	0.7	0
454	Cytomegalovirus in Haematological Tumours. <i>Frontiers in Immunology</i> , 2021, 12, 703256.	2.2	11
455	Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. <i>Leukemia</i> , 2022, 36, 856-864.	3.3	26
456	Cytomegalovirus in primary immunodeficiency. <i>Current Opinion in Infectious Diseases</i> , 2021, Publish Ahead of Print, 663-671.	1.3	6
457	Caught in the antiviral crossfire: Ganciclovir-associated mutagenesis in HSC transplant recipients. <i>Cell Stem Cell</i> , 2021, 28, 1683-1685.	5.2	1
458	Hematopoietic Stem Cell Transplantation. , 2017, , .		0
459	Optimal Management Approach to Prevent Cytomegalovirus Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. , 2018, 15, .		0
460	Antimicrobial Prophylaxis in High-Risk Oncology Patients. , 2019, , 1-15.		0
461	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis. <i>Clinical Hematology International</i> , 2019, 1, 105-113.	0.7	18
462	Clinical Features and Treatment Outcomes of Hematopoietic Stem Cell Transplantation During 2006-2016 at a Single Institution in Miyazaki Prefecture. <i>Journal of Hematopoietic Cell Transplantation</i> , 2019, 8, 122-134.	0.1	0
463	Neue Arzneimittel 2018. , 2019, , 61-175.		1
464	Allogeneic Stem Cell Transplantation with CD34+ Cell Selection. <i>Clinical Hematology International</i> , 2019, 1, 154-160.	0.7	5

#	ARTICLE	IF	CITATIONS
465	POSSIBILITIES OF PREVENTION AND TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTIONS INCLUDING NEW DRUGS AND COMPOUNDS WITH POTENTIAL APPLICATION. Postepy Mikrobiologii, 2019, 58, 291-299.	0.1	1
467	MANAGEMENTS OF CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION. Japanese Journal of Transfusion and Cell Therapy, 2019, 65, 519-524.	0.1	0
468	Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit. , 2020, , 169-199.		0
469	Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation. Journal of the Advanced Practitioner in Oncology, 2019, 10, 730-735.	0.2	0
470	Stem Cell Transplantation: Infection Risk by Transplant Type and Emerging Trends in Infection Management. , 2020, , 1-41.		0
471	Pharmacokinetics and Safety of Letermovir and Midazolam Coadministration in Healthy Subjects. Clinical Pharmacology in Drug Development, 2021, , .	0.8	7
472	Umbilical Cord Blood Transplantation after Graft Failure from a Previous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 46.e1-46.e7.	0.6	4
473	Infecci3n por citomegalovirus resistente en un paciente trasplantado. Uso de letermovir y retirada de la inmunosupresi3n. Nefrologia, 2021, , .	0.2	0
474	Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants. Annals of Hematology, 2022, 101, 409-419.	0.8	2
475	Pulmonary Syndromes in Transplantation. , 2020, , 1-24.		0
476	Antimicrobial Prophylaxis in High-Risk Oncology Patients. , 2020, , 153-167.		0
477	Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients: Prevention, Diagnosis, and Treatment. , 2020, , 1-44.		1
478	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2020, 75, 2253-2257.	1.3	8
479	Cytomegalovirus in Solid Organ Transplant Recipients: Prevention, Diagnosis, and Treatment. , 2020, , 1-25.		0
480	Antimicrobial Prophylaxis in the Age of Emerging Transplant Infections. , 2020, , 1-17.		0
481	Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease. Cancers, 2021, 13, 5572.	1.7	13
482	How I manage infection risk and prevention in patients with lymphoid cancer. Blood, 2022, 139, 1517-1528.	0.6	3
483	Antiviral Prophylaxis. Hematologic Malignancies, 2021, , 37-47.	0.2	0

#	ARTICLE	IF	CITATIONS
484	Top-ten infections in onco-hematological patients (2015-2017). <i>Revista Espanola De Quimioterapia</i> , 2018, 31 Suppl 1, 47-51.	0.5	1
485	Update in Infectious Diseases 2018. <i>Revista Espanola De Quimioterapia</i> , 2018, 31 Suppl 1, 1-8.	0.5	1
486	Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 574-584.	2.5	6
487	Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12858.	1.8	23
488	Letermovir treatment for CMV infection in kidney and pancreas transplantation: A valuable option for complicated cases. <i>Clinical Transplantation</i> , 2022, 36, e14537.	0.8	9
489	Safety and Effectiveness of Letermovir in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan. <i>Clinical Drug Investigation</i> , 2021, 41, 1075-1086.	1.1	5
490	Combined Analysis of Early CD4+ T Cell Counts and CMV Serostatus May Improve CMV Risk Assessment after Allogeneic Hematopoietic Cell Transplantation. <i>Cells</i> , 2021, 10, 3318.	1.8	2
491	Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity. <i>Transplant Infectious Disease</i> , 2022, 24, e13766.	0.7	12
492	The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-glycoprotein Substrate Digoxin in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2021, . .	0.8	1
493	Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 663-680.	2.0	0
495	The EHA Research Roadmap: Infections in Hematology. <i>HemaSphere</i> , 2021, 5, e662.	1.2	5
496	High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 130-137.	0.5	2
497	The Role of $\gamma\delta$ T Cells as a Line of Defense in Viral Infections after Allogeneic Stem Cell Transplantation: Opportunities and Challenges. <i>Viruses</i> , 2022, 14, 117.	1.5	7
498	Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 795-804.	2.9	20
499	Chitosan/benzyloxy-benzaldehyde modified ZnO nano template having optimized and distinct antiviral potency to human cytomegalovirus. <i>Carbohydrate Polymers</i> , 2022, 278, 118965.	5.1	23
500	Immune restoration therapy for multidrug-resistant CMV disease in an allogeneic stem cell transplant recipient. <i>Current Research in Translational Medicine</i> , 2022, 70, 103329.	1.2	2
501	Risk of Cytomegalovirus Infection with Post-Transplantation Cyclophosphamide in Haploidentical and HLA-Matched Unrelated Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 213.e1-213.e6.	0.6	10
502	Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience. <i>Frontiers in Medicine</i> , 2021, 8, 807527.	1.2	5

#	ARTICLE	IF	CITATIONS
503	Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 664-675.	2.3	11
504	Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal. <i>International Journal of Hematology</i> , 2022, 115, 158-162.	0.7	4
505	HLA 1³ antigenµ mismatched related peripheral blood stem cells transplantation using lowµ dose antithymocyte globulin versus unrelated cord blood transplantation. <i>American Journal of Hematology</i> , 2022, 97, 311-321.	2.0	2
506	Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients. <i>Cytotherapy</i> , 2022, 24, 428-436.	0.3	2
507	The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands. <i>European Journal of Haematology</i> , 2022, 108, 327-335.	1.1	4
508	Post-transplant GVHD in the era of molecularly targeted therapy. <i>Journal of Illusion</i> , 2022, 11, 53-63.	0.0	0
509	The Synthesis and Anti-Cytomegalovirus Activity of Piperidine-4-Carboxamides. <i>Viruses</i> , 2022, 14, 234.	1.5	1
510	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 562-571.	1.3	16
511	QuantIFERONµ cytomegalovirus to predict clinically significant cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	4
513	Letermovir and maribavir for panµ resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 699-702.	0.7	5
514	Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 211.e1-211.e9.	0.6	18
515	Two-Metal Ion-Dependent Enzymes as Potential Antiviral Targets in Human Herpesviruses. <i>MBio</i> , 2022, , e0322621.	1.8	4
516	Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance. <i>Frontiers in Microbiology</i> , 2022, 13, 771978.	1.5	7
517	Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. <i>Blood Advances</i> , 2022, 6, 2897-2907.	2.5	13
518	Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells. <i>Transplant Immunology</i> , 2022, 71, 101539.	0.6	12
519	Prognostic factors and impact of CMV reactivation on acute myeloid leukemia patients after HLA-matched myeloablative allogeneic stem cell transplantation in a high CMV prevalence country. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, 45, S51-S56.	0.1	2
520	Infectious Complications in Paediatric Haematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Current Status. <i>Frontiers in Pediatrics</i> , 2021, 9, 782530.	0.9	7
521	Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2022, 12, 781479.	1.3	2

#	ARTICLE	IF	CITATIONS
522	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 265.e1-265.e9.	0.6	6
523	Antiviral Therapeutics in Pediatric Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 125-146.	1.9	2
524	Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 337-340.	0.6	16
525	Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection. <i>Antiviral Therapy</i> , 2022, 27, 135965352110609.	0.6	2
526	Editorial: Strengths and Challenges of Allo-SCT in the Modern Era. <i>Frontiers in Oncology</i> , 2022, 12, 850403.	1.3	1
527	Cyclin-Dependent Kinases (CDKs) and the Human Cytomegalovirus-Encoded CDK Ortholog pUL97 Represent Highly Attractive Targets for Synergistic Drug Combinations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2493.	1.8	12
528	Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 323-327.	1.5	15
529	Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2022, 63, 1925-1933.	0.6	4
530	When Viruses Meet Fungi: Tackling the Enemies in Hematology. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 184.	1.5	0
531	Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 420-428.	0.8	2
532	Preferred Therapy for Specific Viral Pathogens. , 2022, , 173-189.		0
533	Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients. <i>Microbiology Spectrum</i> , 2022, 10, e0019122.	1.2	11
534	Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 938-948.	0.8	5
535	A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 862526.	1.8	7
536	Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Medicine</i> , 2022, 11, 1364.	1.0	7
537	Risk Factors for Early Cytomegalovirus Reactivation and Impact of Early Cytomegalovirus Reactivation on Clinical Outcomes after T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 169.e1-169.e9.	0.6	7
538	Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program. <i>Journal of Clinical Virology</i> , 2022, 148, 105106.	1.6	10
539	Haploidentical Stem Cell Transplantation After TCR- $\alpha\beta$ + and CD19+ Cells Depletion In Children With Congenital Non-Malignant Disease. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 394.e1-394.e9.	0.6	10

#	ARTICLE	IF	CITATIONS
540	Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 508-515.	0.3	13
541	The changing impact of cytomegalovirus among hematopoietic cell transplant recipients during the past decade: A single institutional cohort study. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	1
542	Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Oncology and Therapy</i> , 2022, 10, 105-122.	1.0	2
543	Evaluation of the Pharmacokinetic Interaction Between Letermovir and Tacrolimus in Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 371.e1-371.e4.	0.6	5
544	Reliable quantification of Cytomegalovirus DNAemia in Letermovir treated patients. <i>Antiviral Research</i> , 2022, 201, 105299.	1.9	7
546	Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2023, 7, 2309-2316.	2.5	6
547	Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. <i>Aids</i> , 2022, Publish Ahead of Print, .	1.0	7
548	Treatment failure cost analysis of Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, , 1-3.	0.6	2
552	Threshold of Quantitative Cytomegalovirus DNA PCR for Preemptive Treatment in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Pediatric Hematology/Oncology</i> , 2022, Publish Ahead of Print, .	0.3	1
553	Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis. <i>International Journal of Hematology</i> , 2022, 116, 258-265.	0.7	8
554	Combined knockdown of RL13 and UL128 for release of cell-free infectivity from recent HCMV isolates. <i>Journal of Virological Methods</i> , 2022, 305, 114537.	1.0	1
555	A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 349-354.	0.6	4
556	Therapeutic Implications of the Microbial Hypothesis of Mental Illness. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 315-351.	0.8	5
557	Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 510.e1-510.e9.	0.6	20
558	Infectious Complications of Transplantation. , 2022, , 1627-1661.		1
559	Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	16
560	Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
561	Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: A single-center retrospective analysis. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1317-1323.	0.8	14

#	ARTICLE	IF	CITATIONS
562	The importance of intermediate-dose Valacyclovir in primary CMV prophylaxis after Allogeneic-stem cell transplantation, and the advantages of step-wise pre-emptive treatment in CMV reactivation. <i>Medical Science and Discovery</i> , 2022, 9, 324-333.	0.1	0
563	Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol). <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
564	Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1335-1344.	2.8	6
565	Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. <i>Blood</i> , 2022, 140, 1408-1418.	0.6	13
566	Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 619.e1-619.e8.	0.6	7
567	Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium. <i>Clinical Microbiology and Infection</i> , 2023, 29, 44-50.	2.8	16
568	Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults. <i>Blood Advances</i> , 2022, 6, 6291-6300.	2.5	11
569	Intra-host diversity of drug-resistant cytomegalovirus: A case report of cytomegalovirus infection after allogeneic hematopoietic cell transplantation. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1415-1418.	0.8	2
570	Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation. <i>Anticancer Research</i> , 2022, 42, 3607-3612.	0.5	16
571	Viral Nucleases from Herpesviruses and Coronavirus in Recombination and Proofreading: Potential Targets for Antiviral Drug Discovery. <i>Viruses</i> , 2022, 14, 1557.	1.5	1
572	Immunocompromised host section: Adoptive T-cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 302-311.	1.3	10
573	Artificial stem cells mediated inflammation-tropic delivery of antiviral drugs for pneumonia treatment. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	5
574	Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	6
575	Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	7
577	Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	1
578	Unravelling ALL: The Keys to Improved Post-Transplant Survival in Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 415-416.	0.6	0
579	Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
580	Time-dependent prediction of mortality and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation using machine learning. <i>American Journal of Hematology</i> , 2022, 97, 1309-1323.	2.0	5

#	ARTICLE	IF	CITATIONS
581	Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. <i>Journal of Infectious Diseases</i> , 2022, 226, 1528-1536.	1.9	5
582	Advances in the treatment of severe combined immunodeficiency. <i>Clinical Immunology</i> , 2022, 242, 109084.	1.4	7
583	Efficacy of Cytomegalovirus Specific Immunoglobulins to Reduce CMV Reactivation in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Pediatric Hematology/Oncology</i> , 0, Publish Ahead of Print, .	0.3	1
584	Cytomegalovirus-specific neutralizing antibodies effectively prevent uncontrolled infection after allogeneic hematopoietic stem cell transplantation. <i>IScience</i> , 2022, 25, 105065.	1.9	0
585	Universal posttransplant cyclophosphamide after allogeneic transplant, a retrospective single institution study. <i>Leukemia Research</i> , 2022, 122, 106934.	0.4	0
586	Intrathecal Cytomegalovirus Immunoglobulin for CMV Encephalitis Post Allogeneic Stem Cell Transplantation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
587	Intrathecal cytomegalovirus immunoglobulin for CMV encephalitis post allogeneic stem cell transplantation. <i>IDCases</i> , 2022, 29, e01608.	0.4	3
588	The Impact of High CMV Viral Load and Refractory CMV Infection on Pediatric HSCT Recipients with Underlying Non-Malignant Disorder. <i>Journal of Clinical Medicine</i> , 2022, 11, 5187.	1.0	3
589	Increasing Proportion of High-risk Cytomegalovirus Donor-positive/Recipient-negative Serostatus in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2023, 107, 988-993.	0.5	6
590	Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective. <i>Expert Review of Hematology</i> , 2022, 15, 789-803.	1.0	3
591	Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation – A retrospective single-center study. <i>Transplant Infectious Disease</i> , 0, , .	0.7	0
592	Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
593	Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients. <i>Clinical Transplantation</i> , 2022, 36, .	0.8	5
594	Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	3
595	Cytomegalovirus infection may be oncoprotective against neoplasms of B-lymphocyte lineage: single-institution experience and survey of global evidence. <i>Virology Journal</i> , 2022, 19, .	1.4	2
596	Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Single-Centre Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 28-39.	0.2	3
597	Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	10
598	A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older. <i>Bone Marrow Transplantation</i> , 2023, 58, 30-38.	1.3	8

#	ARTICLE	IF	CITATIONS
599	Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2023, 108, 1530-1543.	1.7	6
600	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. <i>Antiviral Research</i> , 2022, 207, 105422.	1.9	8
602	CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases. <i>Minerva Medica</i> , 0, , .	0.3	0
603	Letermovir as Cytomegalovirus Prophylaxis in a Pediatric Cohort: A Retrospective Analysis. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 62.e1-62.e4.	0.6	12
604	Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	15
605	Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection. <i>Viruses</i> , 2022, 14, 2370.	1.5	9
606	Therapie von Infektionen bei Tumorpatienten. <i>Springer Reference Medizin</i> , 2022, , 1-37.	0.0	0
607	Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis. <i>Anticancer Research</i> , 2022, 42, 5431-5441.	0.5	4
608	Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients. <i>Annual Review of Medicine</i> , 2023, 74, 89-105.	5.0	7
609	Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
610	The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients. <i>Blood Advances</i> , 2023, 7, 856-865.	2.5	9
611	Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia. <i>Cancer Medicine</i> , 0, , .	1.3	2
612	Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients. <i>Antiviral Therapy</i> , 2022, 27, 135965352211336.	0.6	3
613	Letermovir and tacrolimus interaction effects in hematopoietic cell transplantation recipients receiving moderate cytochrome P450 3A4 inhibitors for antifungal prophylaxis. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211397.	0.5	1
614	New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2023, 58, 203-208.	1.3	13
615	<i>Antiviral Agents</i> . , 2023, , 1583-1598.e6.		1
616	<i>Clinical Syndromes of Infection in Children With Cancer</i> . , 2023, , 604-610.e3.		0
617	Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis. <i>Transplant Immunology</i> , 2023, 76, 101769.	0.6	5

#	ARTICLE	IF	CITATIONS
618	A Drugâ€Drug Interaction Study with Letemovir and Acyclovir in Healthy Participants. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	0
619	Evaluation of Two Different CMV-Immunoglobulin Regimens for Combined CMV Prophylaxis in High-Risk Patients following Lung Transplant. <i>Microorganisms</i> , 2023, 11, 32.	1.6	1
620	Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 227-235.	1.3	0
621	Effective CMV prophylaxis with highâ€dose valaciclovir in allogeneic hematopoietic stemâ€cell recipients at a high risk of CMV infection. <i>Transplant Infectious Disease</i> , 2023, 25, .	0.7	3
622	Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease. <i>Leukemia Research</i> , 2023, 125, 107005.	0.4	4
623	Letemovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients. <i>Paediatric Drugs</i> , 2023, 25, 225-232.	1.3	12
624	Therapie von Infektionen bei Tumorpatienten. <i>Springer Reference Medizin</i> , 2023, , 1-37.	0.0	0
625	Real-World Outcomes Associated With Letemovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	17
626	Cytomegalovirus (CMV) Viremia in People With Human Immunodeficiency Virus (HIV): Should We Treat the CMV? or the HIV? or Both?. <i>Clinical Infectious Diseases</i> , 2023, 76, 975-976.	2.9	2
627	Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation. <i>Blood Advances</i> , 2023, 7, 1394-1403.	2.5	4
628	T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy. <i>Blood Advances</i> , 2023, 7, 2155-2165.	2.5	9
630	Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirusâ€specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis. <i>American Journal of Hematology</i> , 2023, 98, 588-597.	2.0	4
631	Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey. <i>Bone Marrow Transplantation</i> , 2023, 58, 414-423.	1.3	2
632	CMV antiviral stewardship: navigating obstacles to facilitate target attainment. <i>Current Opinion in Organ Transplantation</i> , 2023, 28, 8-14.	0.8	3
633	New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease. <i>Infectious Diseases and Therapy</i> , 2023, 12, 333-342.	1.8	15
634	The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients. <i>Clinical Hematology International</i> , 2023, 5, 21-28.	0.7	1
635	CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2023, 7, 2699-2708.	2.5	5
636	Successful Treatment with Letemovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia. <i>International Heart Journal</i> , 2023, , .	0.5	0

#	ARTICLE	IF	CITATIONS
637	Cytomegalovirus breakthrough and resistance during letermovir prophylaxis. Bone Marrow Transplantation, 2023, 58, 430-436.	1.3	8
638	Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond. HemaSphere, 2023, 7, e809.	1.2	5
639	Evaluation of the inhibitory effects of itraconazole on letermovir. British Journal of Clinical Pharmacology, 2023, 89, 2122-2130.	1.1	1
640	Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study. Journal of Fungi (Basel, Switzerland), 2023, 9, 166.	1.5	4
641	Personalized hematopoietic stem cell transplantation for inborn errors of immunity. Frontiers in Immunology, 0, 14, .	2.2	4
642	Inhibition of the hERG potassium ion channel by different non-nucleoside human cytomegalovirus polymerase antiviral inhibitor series and the exploration of variations on a pyrroloquinoline core to reduce cardiotoxicity potential. Bioorganic and Medicinal Chemistry, 2023, 85, 117276.	1.4	0
643	Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem cell transplant recipients during prophylaxis with letermovir. Transplant Infectious Disease, 2023, 25, .	0.7	2
644	Diagnosis and Detection of Congenital Diseases in New-Borns or Fetuses Using Artificial Intelligence Techniques: A Systematic Review. Archives of Computational Methods in Engineering, 2023, 30, 3031-3058.	6.0	4
645	Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation. Haematologica, 2023, 108, 2080-2090.	1.7	2
646	Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party. Bone Marrow Transplantation, 2023, 58, 603-606.	1.3	3
647	Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States. Pharmacoeconomics - Open, 2023, 7, 393-404.	0.9	4
648	CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transplantation, 2023, 58, 639-646.	1.3	6
649	Preferred Therapy for Specific Viral Pathogens. , 2023, , .		0
650	Antiviral therapy defiant mixed viral retinitis post hematopoietic allogeneic stem cell transplant. Clinical Case Reports (discontinued), 2023, 11, .	0.2	1
651	Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships. Transplantation and Cellular Therapy, 2023, 29, 394.e1-394.e7.	0.6	1
652	Harnessing the Noncanonical Keap1-Nrf2 Pathway for Human Cytomegalovirus Control. Journal of Virology, 2023, 97, .	1.5	0
653	Immunologic Monitoring after Allogeneic Stem Cell Transplantation: T-SPOT.CMV and QuantiFERON-CMV, Are They the Same?. Transplantation and Cellular Therapy, 2023, 29, 392.e1-392.e7.	0.6	6
654	Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. Clinical Microbiology and Infection, 2023, 29, 1144-1149.	2.8	8

#	ARTICLE	IF	CITATIONS
728	Allogeneic Hematopoietic Cell Transplantation in CML: When and How?. , 2023, , 653-661.		0
733	Bone Marrow and Haemopoietic Stem Cell Transplantation. , 2023, , 121-129.		0
741	CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplantation, 2024, 59, 138-140.	1.3	2
768	Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2024, 59, 564-565.	1.3	0
781	Preferred Therapy for Specific Viral Pathogens. , 2024, , .		0